<p>Allogene Therapeutics, Inc.（纳斯达克代码：ALLO - 获取免费报告）周二上涨了 10.3%。该公司交易最高达到 2.29 美元，最后交易价格为 2.2950 美元。在交易期间，共交易了约 5,363,671 股，较平均每日交易量 5,955,742 股下降了 10%。该股票此前收盘价为 2.08 美元。</p>
<p>获取 <strong>Allogene Therapeutics</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<ul>
<li>3 只空头头寸水平极高的股票</li>
</ul>
<p>多家研究公司最近对 ALLO 进行了评估。瑞银集团在 1 月 7 日的研究报告中开始覆盖 Allogene Therapeutics 的股票。他们给予该公司 “买入” 评级，并设定 8.00 美元的目标价。Citizens Jmp 在 1 月 9 日的报告中将 Allogene Therapeutics 的股票评级从 “市场表现” 上调至 “跑赢大盘”，并设定 5.00 美元的目标价。花旗集团在 1 月 9 日的研究报告中将 Allogene Therapeutics 的股票评级从 “市场表现” 上调至 “跑赢大盘”。最后，华尔街 Zen 在周日的研究报告中将 Allogene Therapeutics 的股票评级从 “卖出” 上调至 “持有”。十位股票研究分析师给予该股票 “买入” 评级，两位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 8.40 美元。</p>
<p><strong>查看我们最新的 ALLO 股票报告</strong></p>
<h2>Allogene Therapeutics 上涨 10.3%</h2>
<ul>
<li>你可能想买的 2 个医疗保健降级股票</li>
</ul>
<p>该公司的市值为 5.1576 亿美元，市盈率为-2.34，贝塔值为 0.60。该公司的 50 日移动平均线为 1.62 美元，200 日移动平均线为 1.37 美元。</p>
<h2>内部人士买卖情况</h2>
<p>在其他 Allogene Therapeutics 的新闻中，执行副总裁 Zachary Roberts 在 2 月 2 日星期一以 1.77 美元的平均价格出售了 35,700 股该公司的股票，总价值为 63,189.00 美元。出售后，该执行副总裁直接持有 581,166 股公司股票，价值约为 1,028,663.82 美元。此交易代表其持股比例减少了 5.79%。该交易已在向 SEC 提交的文件中披露，您可以通过此链接访问。此外，首席执行官 David D. Chang 在 2 月 2 日星期一以 1.80 美元的平均价格出售了 95,269 股该公司的股票，总交易额为 171,484.20 美元。交易后，首席执行官直接持有 5,185,862 股公司股票，价值约为 9,334,551.60 美元。此交易代表其持股比例减少了 1.80%。有关此销售的更多详细信息可在官方 SEC 披露中找到。在过去 90 天内，内部人士出售了 215,855 股公司股票，价值 378,426 美元。公司内部人士持有公司股票的 13.20%。</p>
<h2>机构投资者对 Allogene Therapeutics 的看法</h2>
<p>机构投资者和对冲基金最近调整了对该股票的持有。Mercer Global Advisors Inc. ADV 在第四季度将其在 Allogene Therapeutics 的股份增加了 23.0%。Mercer Global Advisors Inc. ADV 现在拥有 29,512 股公司股票，价值 40,000 美元，此前在该期间内购买了 5,514 股。加拿大人寿保险公司在第三季度将其在 Allogene Therapeutics 的股份增加了 27.3%。加拿大人寿保险公司现在拥有 39,730 股公司股票，价值 50,000 美元，此前在上个季度购买了 8,519 股。Quadrature Capital Ltd 在第二季度将其在 Allogene Therapeutics 的股份增加了 29.6%。Quadrature Capital Ltd 现在拥有 44,050 股公司股票，价值 50,000 美元，此前在该期间内购买了 10,059 股。Brighton Jones LLC 在第三季度将其在 Allogene Therapeutics 的股份增加了 81.6%。Brighton Jones LLC 现在拥有 25,168 股公司股票，价值 31,000 美元，此前在上个季度购买了 11,311 股。最后，Zacks Investment Management 在第三季度将其在 Allogene Therapeutics 的股份增加了 2.7%。Zacks Investment Management 现在拥有 526,132 股公司股票，价值 652,000 美元，此前在该期间内购买了 13,831 股。机构投资者和对冲基金持有公司股票的 83.63%。</p>
<h2>Allogene Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Allogene Therapeutics 是一家临床阶段的生物技术公司，专注于开发同种异体或 “现成” 的嵌合抗原受体 T 细胞（CAR T）疗法，以治疗一系列血液恶性肿瘤和实体肿瘤。该公司利用基因编辑技术生成普遍兼容的工程 T 细胞，旨在克服患者特定 CAR T 方法的局限性，如生产延迟、产品质量不稳定和治疗抵抗。</p>
<p>该公司的产品管线包括多个针对血癌关键抗原的同种异体 CAR T 候选药物。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Allogene Therapeutics</li>
<li>当今最大科技趋势背后的基础</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>家族信托如何帮助保护您的财富</li>
<li>这让我感到愤怒</li>
<li>没有人谈论的免费股票推荐</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Allogene Therapeutics 吗？</h2>
<p>在考虑 Allogene Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Allogene Therapeutics 并不在名单上。</p>
<p>虽然 Allogene Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

ALLO

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

IBBQ

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Allogene Therapeutics (NASDAQ:ALLO) 的股价上涨了 10.3%，达到 2.2950 美元，成交量为 536 万股。分析师给予的共识评级为 “适度买入”，平均目标价为 8.40 美元。最近的内部交易包括执行副总裁 Zachary Roberts 和首席执行官 David D. Chang 的出售。机构投资者持有该股票的 83.63%。Allogene 专注于开发用于血液恶性肿瘤和实体肿瘤的异基因 CAR T 疗法，利用基因编辑技术</p>

<p>Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) rose 10.3% on Tuesday . The company traded as high as $2.29 and last traded at $2.2950. Approximately 5,363,671 shares were traded during trading, a decline of 10% from the average daily volume of 5,955,742 shares. The stock had previously closed at $2.08.</p>
<div class="lb-trans"><p>Allogene Therapeutics, Inc.（纳斯达克代码：ALLO - 获取免费报告）周二上涨了 10.3%。该公司交易最高达到 2.29 美元，最后交易价格为 2.2950 美元。在交易期间，共交易了约 5,363,671 股，较平均每日交易量 5,955,742 股下降了 10%。该股票此前收盘价为 2.08 美元。</p>
</div><p>Get <strong>Allogene Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Allogene Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>3 Stocks With Sky-High Short Interest Levels</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只空头头寸水平极高的股票</li>
</ul>
</div><p>A number of research firms have recently weighed in on ALLO. UBS Group started coverage on shares of Allogene Therapeutics in a research report on Wednesday, January 7th. They set a &#34;buy&#34; rating and a $8.00 price target for the company. Citizens Jmp raised shares of Allogene Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $5.00 price objective for the company in a report on Friday, January 9th. Citigroup raised shares of Allogene Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a research report on Friday, January 9th. Finally, Wall Street Zen raised shares of Allogene Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday. Ten equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $8.40.</p>
<div class="lb-trans"><p>多家研究公司最近对 ALLO 进行了评估。瑞银集团在 1 月 7 日的研究报告中开始覆盖 Allogene Therapeutics 的股票。他们给予该公司 “买入” 评级，并设定 8.00 美元的目标价。Citizens Jmp 在 1 月 9 日的报告中将 Allogene Therapeutics 的股票评级从 “市场表现” 上调至 “跑赢大盘”，并设定 5.00 美元的目标价。花旗集团在 1 月 9 日的研究报告中将 Allogene Therapeutics 的股票评级从 “市场表现” 上调至 “跑赢大盘”。最后，华尔街 Zen 在周日的研究报告中将 Allogene Therapeutics 的股票评级从 “卖出” 上调至 “持有”。十位股票研究分析师给予该股票 “买入” 评级，两位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 8.40 美元。</p>
</div><p><strong>View Our Latest Stock Report on ALLO</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 ALLO 股票报告</strong></p>
</div><h2>Allogene Therapeutics Trading Up 10.3%</h2>
<div class="lb-trans"><h2>Allogene Therapeutics 上涨 10.3%</h2>
</div><ul>
<li>2 Downgrades in Healthcare You Might Want to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>你可能想买的 2 个医疗保健降级股票</li>
</ul>
</div><p>The firm has a market cap of $515.76 million, a P/E ratio of -2.34 and a beta of 0.60. The business's 50-day moving average is $1.62 and its two-hundred day moving average is $1.37.</p>
<div class="lb-trans"><p>该公司的市值为 5.1576 亿美元，市盈率为-2.34，贝塔值为 0.60。该公司的 50 日移动平均线为 1.62 美元，200 日移动平均线为 1.37 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖情况</h2>
</div><p>In other Allogene Therapeutics news, EVP Zachary Roberts sold 35,700 shares of the firm's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $1.77, for a total value of $63,189.00. Following the sale, the executive vice president directly owned 581,166 shares in the company, valued at approximately $1,028,663.82. This trade represents a 5.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO David D. Chang sold 95,269 shares of the business's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.80, for a total transaction of $171,484.20. Following the transaction, the chief executive officer directly owned 5,185,862 shares of the company's stock, valued at approximately $9,334,551.60. This trade represents a 1.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 215,855 shares of company stock worth $378,426. Company insiders own 13.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Allogene Therapeutics 的新闻中，执行副总裁 Zachary Roberts 在 2 月 2 日星期一以 1.77 美元的平均价格出售了 35,700 股该公司的股票，总价值为 63,189.00 美元。出售后，该执行副总裁直接持有 581,166 股公司股票，价值约为 1,028,663.82 美元。此交易代表其持股比例减少了 5.79%。该交易已在向 SEC 提交的文件中披露，您可以通过此链接访问。此外，首席执行官 David D. Chang 在 2 月 2 日星期一以 1.80 美元的平均价格出售了 95,269 股该公司的股票，总交易额为 171,484.20 美元。交易后，首席执行官直接持有 5,185,862 股公司股票，价值约为 9,334,551.60 美元。此交易代表其持股比例减少了 1.80%。有关此销售的更多详细信息可在官方 SEC 披露中找到。在过去 90 天内，内部人士出售了 215,855 股公司股票，价值 378,426 美元。公司内部人士持有公司股票的 13.20%。</p>
</div><h2>Institutional Investors Weigh In On Allogene Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Allogene Therapeutics 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV boosted its position in shares of Allogene Therapeutics by 23.0% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 29,512 shares of the company's stock valued at $40,000 after purchasing an additional 5,514 shares during the period. CANADA LIFE ASSURANCE Co lifted its stake in Allogene Therapeutics by 27.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 39,730 shares of the company's stock valued at $50,000 after buying an additional 8,519 shares in the last quarter. Quadrature Capital Ltd boosted its holdings in shares of Allogene Therapeutics by 29.6% in the second quarter. Quadrature Capital Ltd now owns 44,050 shares of the company's stock worth $50,000 after buying an additional 10,059 shares during the period. Brighton Jones LLC increased its position in shares of Allogene Therapeutics by 81.6% in the third quarter. Brighton Jones LLC now owns 25,168 shares of the company's stock worth $31,000 after acquiring an additional 11,311 shares in the last quarter. Finally, Zacks Investment Management raised its holdings in shares of Allogene Therapeutics by 2.7% during the third quarter. Zacks Investment Management now owns 526,132 shares of the company's stock valued at $652,000 after acquiring an additional 13,831 shares during the period. Institutional investors and hedge funds own 83.63% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近调整了对该股票的持有。Mercer Global Advisors Inc. ADV 在第四季度将其在 Allogene Therapeutics 的股份增加了 23.0%。Mercer Global Advisors Inc. ADV 现在拥有 29,512 股公司股票，价值 40,000 美元，此前在该期间内购买了 5,514 股。加拿大人寿保险公司在第三季度将其在 Allogene Therapeutics 的股份增加了 27.3%。加拿大人寿保险公司现在拥有 39,730 股公司股票，价值 50,000 美元，此前在上个季度购买了 8,519 股。Quadrature Capital Ltd 在第二季度将其在 Allogene Therapeutics 的股份增加了 29.6%。Quadrature Capital Ltd 现在拥有 44,050 股公司股票，价值 50,000 美元，此前在该期间内购买了 10,059 股。Brighton Jones LLC 在第三季度将其在 Allogene Therapeutics 的股份增加了 81.6%。Brighton Jones LLC 现在拥有 25,168 股公司股票，价值 31,000 美元，此前在上个季度购买了 11,311 股。最后，Zacks Investment Management 在第三季度将其在 Allogene Therapeutics 的股份增加了 2.7%。Zacks Investment Management 现在拥有 526,132 股公司股票，价值 652,000 美元，此前在该期间内购买了 13,831 股。机构投资者和对冲基金持有公司股票的 83.63%。</p>
</div><h2>Allogene Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Allogene Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.</p>
<div class="lb-trans"><p>Allogene Therapeutics 是一家临床阶段的生物技术公司，专注于开发同种异体或 “现成” 的嵌合抗原受体 T 细胞（CAR T）疗法，以治疗一系列血液恶性肿瘤和实体肿瘤。该公司利用基因编辑技术生成普遍兼容的工程 T 细胞，旨在克服患者特定 CAR T 方法的局限性，如生产延迟、产品质量不稳定和治疗抵抗。</p>
</div><p>The company's pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个针对血癌关键抗原的同种异体 CAR T 候选药物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Allogene Therapeutics</li>
<li>The Foundation Behind Today's Biggest Tech Trends</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>This makes me furious</li>
<li>The free stock picks nobody’s talking about</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Allogene Therapeutics</li>
<li>当今最大科技趋势背后的基础</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>家族信托如何帮助保护您的财富</li>
<li>这让我感到愤怒</li>
<li>没有人谈论的免费股票推荐</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Allogene Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Allogene Therapeutics 吗？</h2>
</div><p>Before you consider Allogene Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Allogene Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Allogene Therapeutics 并不在名单上。</p>
</div><p>While Allogene Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Allogene Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Allogene Therapeutics (NASDAQ:ALLO) Shares Up 10.3%  - Should You Buy?

Market Beat

Allogene Therapeutics

Invesco Nasdaq Biotechnology ETF

Allogene Therapeutics (NASDAQ:ALLO) 的股价上涨了 10.3% - 你是否应该购买？